Clinical Trials

2 enrolled 10 charts

Phase 1 Active not recruiting

Neoplasms, Pancreatic Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03250273 2025-05-28

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

44 enrolled 19 charts

Phase 1 Active not recruiting

Neoplasm Metastasis, Pancreatic Neoplasms, Cholangiocarcinoma

NCT06532331 2025-04-18

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

87 enrolled

Pancreatic Neoplasms

NCT04925284 2025-04-04

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

BreastGastrointestinalGynecologicThoracic

269 enrolled

Carcinoma, Ovarian Epithelial, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04247165 2025-03-12

LAPTOP

55 enrolled

Pancreatic Neoplasms

NCT06538207 2025-02-06

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

46 enrolled

Pancreatic Neoplasms

NCT03161379 2025-02-03

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

31 enrolled 9 charts

Pancreatic Neoplasms

NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

79 enrolled

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT06532344 2024-11-14

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1 Active not recruiting

32 enrolled

Pancreatic Neoplasms

NCT03565445 2024-11-01

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & Neck

190 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04098432 2024-09-23

CA209-9KH

15 enrolled

Phase EARLY_PHASE1 Active not recruiting

Pancreatic Neoplasms

NCT05482451 2024-08-21

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

10 enrolled

Pancreatic Neoplasms

NCT05116917 2024-05-28

INFLUENCE

Phase 2 Terminated

19 enrolled

Influenza, Human, Pancreatic Neoplasms

NCT03373188 2024-03-20

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

10 enrolled

Phase EARLY_PHASE1 Terminated

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03519308 2024-03-15

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

3 enrolled 13 charts

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05088889 2023-11-28

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Phase 1 Unknown

10 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Pancreatic Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05435053 2023-09-15

CHECKPOINT

Phase 2 Terminated

9 enrolled

Pancreatic Neoplasms

NCT03953235 2023-09-13

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

39 enrolled

GastrointestinalThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04953962 2023-08-15

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

36 enrolled

Pancreatic Neoplasms

NCT04050085 2023-08-01

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

6 enrolled

Pancreatic Neoplasms

NCT04212026 2023-07-18

Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.

Phase 2 Terminated

8 enrolled

Pancreatic Neoplasms

NCT03829436 2023-07-03

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors